Fundraising Fox
Apollomics
Foster City, US · Founded 2015 · 25 employees on LinkedIn · 3 known investors
Find your way into Apollomics
Sign up to find every way you can get introduced to Apollomics
- Your email: who you already know at Apollomics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Apollomics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed to combine with other treatments, using approaches that engage the immune system and target specific molecular pathways to inhibit cancer. It operates as a publicly traded (Nasdaq-listed) drug developer with clinical programs including vebreltinib (APL-101).
Founders & leadership
Board
Investors · 3
How we know: Maxpro Ventures's portfolio page · Not right? Tell us
How we know: Pan-Lin Capital's portfolio page · Not right? Tell us
How we know: Qiming Venture Partners's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2026
▶$10MraisedAug 2026 · 8 investors · BiotechnologyRule 506(b)
- Hung-Wen (Howard) ChenExecutive Officer, Director
- Hung-Hsien YenDirector
- Yi-Kuei (Alex) ChenExecutive Officer, Director
- Hong-Jung (Moses) ChenDirector
- Hsien-Shu (Jerry) TsaiDirector
- Ya-Chi (Claudia) HuangDirector
- Peter LinExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $100K
- First sale
- Aug 2026
- Incorporated
- Corporation, Cayman Islands
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Apollomics do?
- Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed to combine with other treatments, using approaches that engage the immune system and target specific molecular pathways to inhibit cancer. It operates as a publicly traded (Nasdaq-listed) drug developer with clinical programs including vebreltinib (APL-101).
- Who are Apollomics's investors?
- Apollomics's investors include Maxpro Ventures, Pan-Lin Capital, Qiming Venture Partners.
- How much funding has Apollomics raised?
- Apollomics has disclosed $10M raised across 1 round.
- Where is Apollomics headquartered?
- Apollomics is headquartered in Foster City, US.